A detailed history of Rhumbline Advisers transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 2,363,341 shares of GILD stock, worth $216 Million. This represents 0.18% of its overall portfolio holdings.

Number of Shares
2,363,341
Previous 2,459,500 3.91%
Holding current value
$216 Million
Previous $169 Million 17.39%
% of portfolio
0.18%
Previous 0.16%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$66.59 - $83.99 $6.4 Million - $8.08 Million
-96,159 Reduced 3.91%
2,363,341 $198 Million
Q2 2024

Aug 01, 2024

SELL
$63.15 - $72.88 $65,549 - $75,649
-1,038 Reduced 0.04%
2,459,500 $169 Million
Q1 2024

May 09, 2024

SELL
$71.58 - $87.29 $25.9 Million - $31.6 Million
-361,652 Reduced 12.81%
2,460,538 $180 Million
Q4 2023

Feb 08, 2024

SELL
$73.27 - $83.09 $2.92 Million - $3.32 Million
-39,919 Reduced 1.39%
2,822,190 $229 Million
Q3 2023

Nov 09, 2023

BUY
$73.94 - $80.67 $5.36 Million - $5.85 Million
72,535 Added 2.6%
2,862,109 $214 Million
Q2 2023

Aug 08, 2023

SELL
$76.01 - $86.7 $241,407 - $275,359
-3,176 Reduced 0.11%
2,789,574 $215 Million
Q1 2023

May 11, 2023

BUY
$77.31 - $88.08 $4.33 Million - $4.93 Million
55,961 Added 2.04%
2,792,750 $232 Million
Q4 2022

Feb 14, 2023

BUY
$62.32 - $89.47 $2.67 Million - $3.83 Million
42,809 Added 1.59%
2,736,789 $235 Million
Q3 2022

Nov 10, 2022

BUY
$59.54 - $68.01 $26.7 Million - $30.5 Million
447,874 Added 19.94%
2,693,980 $166 Million
Q2 2022

Aug 11, 2022

BUY
$57.72 - $65.01 $6.18 Million - $6.96 Million
107,019 Added 5.0%
2,246,106 $139 Million
Q1 2022

May 12, 2022

BUY
$57.92 - $72.58 $1.98 Million - $2.48 Million
34,162 Added 1.62%
2,139,087 $127 Million
Q4 2021

Feb 10, 2022

BUY
$64.88 - $73.64 $2.46 Million - $2.79 Million
37,900 Added 1.83%
2,104,925 $153 Million
Q3 2021

Nov 12, 2021

SELL
$67.69 - $73.03 $4.53 Million - $4.89 Million
-66,949 Reduced 3.14%
2,067,025 $144 Million
Q2 2021

Aug 05, 2021

SELL
$63.47 - $69.35 $7.87 Million - $8.6 Million
-123,970 Reduced 5.49%
2,133,974 $147 Million
Q1 2021

May 06, 2021

SELL
$60.0 - $68.46 $7.28 Million - $8.31 Million
-121,318 Reduced 5.1%
2,257,944 $146 Million
Q4 2020

Feb 10, 2021

SELL
$56.65 - $64.55 $7.47 Million - $8.52 Million
-131,937 Reduced 5.25%
2,379,262 $139 Million
Q3 2020

Nov 12, 2020

SELL
$62.1 - $78.08 $459,788 - $578,104
-7,404 Reduced 0.29%
2,511,199 $159 Million
Q2 2020

Aug 13, 2020

BUY
$72.34 - $84.0 $19.6 Million - $22.8 Million
271,391 Added 12.08%
2,518,603 $194 Million
Q1 2020

May 06, 2020

BUY
$62.63 - $80.22 $2.81 Million - $3.6 Million
44,892 Added 2.04%
2,247,212 $168 Million
Q4 2019

Feb 05, 2020

BUY
$61.62 - $67.78 $1.78 Million - $1.96 Million
28,860 Added 1.33%
2,202,320 $143 Million
Q3 2019

Oct 23, 2019

BUY
$62.51 - $69.0 $2.68 Million - $2.96 Million
42,854 Added 2.01%
2,173,460 $138 Million
Q2 2019

Aug 14, 2019

SELL
$61.87 - $69.38 $789,399 - $885,219
-12,759 Reduced 0.6%
2,130,606 $144 Million
Q1 2019

May 01, 2019

BUY
$62.53 - $70.05 $3.55 Million - $3.97 Million
56,702 Added 2.72%
2,143,365 $139 Million
Q4 2018

Jan 31, 2019

BUY
$60.54 - $79.0 $116,176 - $151,601
1,919 Added 0.09%
2,086,663 $131 Million
Q3 2018

Nov 07, 2018

SELL
$71.28 - $78.92 $2.22 Million - $2.46 Million
-31,147 Reduced 1.47%
2,084,744 $161 Million
Q2 2018

Aug 06, 2018

SELL
$64.88 - $75.68 $15 Million - $17.4 Million
-230,447 Reduced 9.82%
2,115,891 $150 Million
Q1 2018

May 02, 2018

SELL
$72.84 - $88.8 $5.43 Million - $6.61 Million
-74,481 Reduced 3.08%
2,346,338 $177 Million
Q4 2017

Feb 09, 2018

BUY
$71.15 - $83.52 $7.18 Million - $8.43 Million
100,935 Added 4.35%
2,420,819 $173 Million
Q3 2017

Nov 06, 2017

BUY
$72.11 - $85.47 $167 Million - $198 Million
2,319,884
2,319,884 $188 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $114B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.